SNN 📈 Smith & Nephew SNATS - Overview

Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US83175M2052

SNN: Knee Implants, Hip Implants, Surgical Instruments, Wound Care Products

Smith & Nephew plc is a leading medical technology company that designs, manufactures, and markets a wide range of innovative medical devices and services globally. The company operates through three main business segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

In the Orthopaedics segment, Smith & Nephew offers a comprehensive portfolio of products for joint reconstruction, including knee and hip implants, as well as trauma and extremities products for fracture stabilization and deformity correction. These products are designed to help patients regain mobility and improve their quality of life.

The Sports Medicine & ENT segment provides a range of products and technologies for minimally invasive surgery, soft tissue repair, and joint reconstruction. This includes arthroscopic enabling technologies, such as fluid management systems, high-definition cameras, and radio frequency devices, which enable surgeons to perform complex procedures with greater precision and accuracy.

In the Advanced Wound Management segment, Smith & Nephew offers a broad range of products and solutions for the treatment and prevention of acute and chronic wounds. This includes advanced wound bioactives, such as biologics and bioactive technologies, as well as advanced wound devices, including negative pressure wound therapy and hydrosurgery systems. These products are designed to promote wound healing, reduce the risk of complications, and improve patient outcomes.

Smith & Nephew's products and services are used by healthcare providers around the world, and the company is committed to delivering innovative solutions that improve patient care and outcomes. With a rich history dating back to 1856, Smith & Nephew is headquartered in Watford, UK, and has a strong presence in over 100 countries globally.

Additional Sources for SNN Stock

SNN Stock Overview

Market Cap in USD 11,035m
Sector Healthcare
Industry Medical Devices
GiC Industry Health Care Equipment & Supplies
TER 0.00%
IPO / Inception 1999-11-16

SNN Stock Ratings

Growth 5y -42.8%
Fundamental 42.1%
Dividend 41.7%
Rel. Performance Sector -1.13
Analysts 4/5
Fair Price Momentum 22.99 USD
Fair Price DCF 14.57 USD

SNN Dividends

Dividend Yield 12m 2.92%
Yield on Cost 5y 1.93%
Annual Growth 5y 0.60%
Payout Consistency 95.28%

SNN Growth Ratios

Growth Correlation 3m -88.5%
Growth Correlation 12m 28.8%
Growth Correlation 5y -76.1%
CAGR 5y -7.95%
CAGR/Mean DD 5y -0.25
Sharpe Ratio 12m 0.07
Alpha -29.75
Beta 0.95
Volatility 24.18%
Current Volume 597.1k
Average Volume 20d 919.6k
What is the price of SNN stocks?
As of December 04, 2024, the stock is trading at USD 25.67 with a total of 597,060 shares traded.
Over the past week, the price has changed by +1.46%, over one month by +1.54%, over three months by -15.49% and over the past year by +1.52%.
Is Smith & Nephew SNATS a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Smith & Nephew SNATS (NYSE:SNN) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 42.08 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SNN as of December 2024 is 22.99. This means that SNN is currently overvalued and has a potential downside of -10.44%.
Is SNN a buy, sell or hold?
Smith & Nephew SNATS has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy SNN.
  • Strong Buy: 2
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecast for SNN stock price target?
According to ValueRays Forecast Model, SNN Smith & Nephew SNATS will be worth about 25.2 in December 2025. The stock is currently trading at 25.67. This means that the stock has a potential downside of -1.83%.
Issuer Forecast Upside
Wallstreet Target Price 32.6 26.8%
Analysts Target Price 31.3 22%
ValueRay Target Price 25.2 -1.8%